Sleep Cycle Moves Sleep Apnea AI Study Validation to US to Bolster Market Push

Sleep Cycle AB ( (SE:SLEEP) ) has shared an update.

Sleep Cycle has signed an agreement with a leading US clinical research organization to run the validation phase of its clinical study for an AI-based sleep apnea screening tool, as the development phase, based on roughly 300 recorded nights, nears completion in the first quarter of 2026 and the full study is scheduled to conclude in September 2026. By shifting validation to the US, the company aims to build a robust, single-country clinical dataset to support regulatory approval, accelerate commercialization and strengthen its positioning in both consumer health and B2B partnerships in a market where sleep apnea is widely underdiagnosed and home-based sleep testing already exceeds SEK 10 billion, with the SEK 30 million validation investment to be capitalized as a development cost and detailed further in the upcoming year-end report.

The most recent analyst rating on (SE:SLEEP) stock is a Buy with a SEK28.00 price target. To see the full list of analyst forecasts on Sleep Cycle AB stock, see the SE:SLEEP Stock Forecast page.

More about Sleep Cycle AB

Sleep Cycle AB is a Swedish-listed sleep technology company that develops consumer-facing digital tools to improve sleep health, centered on its mobile app that uses proprietary, patented sound-analysis AI to track sleep patterns and flag potential sleep issues. With more than 3 billion analyzed sleep sessions, the company targets both individual consumers and corporate partners through in-app offerings, software development kits and data-driven sleep insights, and counts the US as its largest single market, generating about 35% of its revenue.

Average Trading Volume: 34,907

Technical Sentiment Signal: Sell

Current Market Cap: SEK512M

Learn more about SLEEP stock on TipRanks’ Stock Analysis page.